India Globalization Capital, Inc. (IGC)
$
0.29
-0.01 (-3.45%)
Key metrics
Financial statements
Free cash flow per share
-0.0645
Market cap
24.4 Million
Price to sales ratio
19.7147
Debt to equity
0.0233
Current ratio
1.1483
Income quality
0.5212
Average inventory
1.5 Million
ROE
-1.2219
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The total costs and expenses for the company are $11,143,000.00 reflecting its overall spending. The weighted average number of diluted shares outstanding is 58,839,868.00 indicating potential dilution effects that may impact shareholders. Additionally, the company incurred an interest expense of $0.00 which highlights its debt servicing obligations. Despite its efforts, the company reported a net loss of -$13,000,000.00 indicating challenges in its operations that it must navigate moving forward. The financial data pertains to the fiscal year 2024 which provides a framework for assessing its performance during this period. India Globalization Capital, Inc. purchases and resells physical infrastructure commodities and operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment and undertakes highway construction contracts while also developing cannabinoid-based products and therapies. The stock is affordable at $0.29 making it suitable for budget-conscious investors looking for entry-level opportunities. However, the stock has a low average trading volume of 387,075.00 suggesting lower market activity and possibly less liquidity for traders. With a market capitalization of $22,710,282.00 the company is classified as a small-cap player, which often appeals to investors interested in potential growth outside of larger corporations. It is a key player in the Conglomerates industry, contributing significantly to the overall market landscape through diverse operational segments. Furthermore, it belongs to the Industrials sector, driving innovation and growth in both physical infrastructure and cannabinoid-related markets. As it continues to expand its offerings and navigate financial challenges, the company exemplifies a blend of traditional and emerging industry practices.
What is India Globalization Capital, Inc. (IGC)'s stock forecast?
Analysts predict India Globalization Capital, Inc. stock to fluctuate between $0.26 (low) and $0.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is India Globalization Capital, Inc.'s market capitalization?
As of 2025-04-01, India Globalization Capital, Inc.'s market cap is $22,710,282, based on 79,685,200 outstanding shares.
How does India Globalization Capital, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., India Globalization Capital, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy India Globalization Capital, Inc. (IGC) stock?
To buy India Globalization Capital, Inc. (IGC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for IGC. Place an order (Market, Limit, etc.).
What is the best time to invest in India Globalization Capital, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did India Globalization Capital, Inc. perform in the last earnings report?
Revenue: $1,345,000 | EPS: -$0.22 | Growth: -0%.
Where can I find India Globalization Capital, Inc.'s investor relations reports?
Visit https://www.igcinc.us/investor-relations for detailed financial reports.
Where can I find historical stock prices for India Globalization Capital, Inc.?
You can explore historical data from here
What is the all-time high and low for India Globalization Capital, Inc. stock?
All-time high: $4.65 (2021-07-22) | All-time low: $0.25 (2023-12-20).
What are the key trends affecting India Globalization Capital, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
accessnewswire.com
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr.
zacks.com
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
zacks.com
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
accessnewswire.com
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
accesswire.com
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery.
accesswire.com
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
accesswire.com
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025.
zacks.com
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
businesswire.com
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment.
See all news
